



PRESS RELEASE

Aenova Group implements new manufacturing facility in Italy

- **New facility will be dedicated to manufacturing of Animal Health products**
- **Project construction realised in only 10 months, under joint investment with Virbac**

Starnberg/Latina (Italy), 16 November 2017. The Aenova Group, one of the world's leading companies in the pharmaceutical and healthcare industry, expands its Animal Health production with a new dedicated manufacturing area for solids veterinary pharmaceuticals in Latina (Italy).

The new production building is an example of a successful partnership with Virbac, one of the top Animal Health veterinary companies globally. The project involves joint investment in the construction of a new manufacturing area, completed within 10 months with modern and state-of-the-art production equipment. The operation will start in March 2018; while the full production capacity of the new facility will be reached in 2019.

"We will continue to expand our strategic and leading market position in the field of veterinary contract manufacturing. Animal Health is a strategic pillar that differentiates Aenova from the traditional CDMOs (Contract Development and Manufacturing Organisation) and the site in Latina is instrumental for this. With this investment, we will be increasing our production capabilities for solids parasiticides, particularly for the US market, with potential for further expansion in this segment ", said Dr Mohammad Naraghi, CEO of the Aenova Group.

"Today our site in Latina is one of the most important manufacturers of veterinary pharmaceuticals for third parties with established commercial relationships with almost all top



Animal Health companies on the market. This result comes from a clear strategy supported by the capability to be competitive on the market and demonstrating to be a reliable partner for our customers”, said Angelo Gatto, Senior Vice President, Global Sales and Marketing of Aenova Group.

The Aenova site in Latina produces pharmaceutical products for both human and veterinary use. The site was founded by Pfizer in 1957, in 2009 it entered the CDMO business. It is structured in four main production areas: production of sterile and non-sterile penicillin drugs, production of sterile cephalosporin drugs as well as the production of conventional medicines, and now the new facility dedicated to veterinary solid doses. The site offers state-of-the-art technology with a high level of automation and integration.

Aenova Group

With a planned turnover of around EUR 750 million in the current financial year, the Aenova Group is one of the leading companies in the global pharmaceutical and healthcare industry. The group's portfolio of services covers the entire value chain for the development and production of all the main dosage forms and product groups in the field of medicines and dietary supplements. The Aenova Group's high standards of quality, innovative technologies and clear vision for the future have enabled it to become the European market leader in the business-to-business field. The company, which has its headquarters in Percha/Starnberg near Munich, operates 27 sites in eleven countries throughout the world. More than 4400 employees contribute to the group's success.

Virbac

Virbac offers veterinarians, farmers and pet owners in more than 100 countries a comprehensive and practical range of products and services. With these innovative solutions covering the majority of animal species and diseases, Virbac contributes, day after day, to shape the future of animal health.



Contact details for questions:

Ralf Geissler
Perfect Game Communications
Lachnerstraße 32
81371 Munich, Germany

Tel.: +49 89 30 90 52 95 20
Mobile: +49 170 904 30 50
Email: rg@perfect-game.de

Iris Pest - Corporate Communications
Aenova Holding GmbH
Berger Straße 8-10
D-82319 Starnberg

Tel: +49 8151 9987-306
Mobile: +49 170 22 331 11
Email: iris.pest@aenova-group.com

